ArticleRheumatology international2009
Disease burden of psoriatic arthritis compared to rheumatoid arthritis, Hungarian experiment.
Article in Rheumatology international, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- The Economic Burden of Inflammatory Arthritis: A Systematic Review.PharmacoEconomics · 2025Pooled it
- Cost-of-illness studies in nine Central and Eastern European countries.The European journal of health economics : HEPAC : health economics in prevention and care · 2019Pooled it
- EQ-5D studies in musculoskeletal and connective tissue diseases in eight Central and Eastern European countries: a systematic literature review and meta-analysis.Rheumatology international · 2017Pooled it
- Transferability of results of cost utility analyses for biologicals in inflammatory conditions for Central and Eastern European countries.The European journal of health economics : HEPAC : health economics in prevention and care · 2014Pooled it
- Sustained improvements in health status and work productivity with bimekizumab in psoriatic arthritis: 2-year results from two phase 3 studies.Rheumatology advances in practice · 2026Article
- Achievement of more stringent disease control is associated with reduced burden on workplace and household productivity: results from long-term certolizumab pegol treatment in patients with psoriatic arthritis.Therapeutic advances in musculoskeletal disease · 2022Article
- Frequency of Health Care Resource Utilization and Direct Medical Costs Associated with Psoriatic Arthritis in a Rheumatic Care Center in Colombia.Psoriasis (Auckland, N.Z.) · 2021Article
- A comparison of European, Polish, Slovenian and British EQ-5D-3L value sets using a Hungarian sample of 18 chronic diseases.The European journal of health economics : HEPAC : health economics in prevention and care · 2019Article
- Novel Concepts in Psoriatic Arthritis Management: Can We Treat to Target?Current rheumatology reports · 2018Review
- Disease activity, quality of life and indirect costs of psoriatic arthritis in Poland.Rheumatology international · 2016Article
- Economic burden of long-term care of rheumatoid arthritis patients in Hungary.The European journal of health economics : HEPAC : health economics in prevention and care · 2014Article
- Changes in the health status of the population of Central and Eastern European countries between 1990 and 2010.The European journal of health economics : HEPAC : health economics in prevention and care · 2014Article
- Cost-of-illness in patients with moderate to severe psoriasis: a cross-sectional survey in Hungarian dermatological centres.The European journal of health economics : HEPAC : health economics in prevention and care · 2014Article
- Biological therapy in inflammatory rheumatic diseases: issues in Central and Eastern European countries.The European journal of health economics : HEPAC : health economics in prevention and care · 2014Review
- Review
- Health-related quality of life and utility in patients receiving biological and non-biological treatments in rheumatoid arthritis.Rheumatology international · 2012Article
- The burden of psoriatic arthritis: a literature review from a global health systems perspective.P & T : a peer-reviewed journal for formulary management · 2010Article
- Costs of dementia in Hungary.The journal of nutrition, health & aging · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The objectives of this study were to assess the costs of psoriatic arthritis (PsA) in Hungary and to identify key cost drivers among demographic and clinical variables and to compare cost-of-illness of PsA and rheumatoid arthritis (RA). Cross-sectional retrospective survey of 183 consecutive patients from eight rheumatology centres was conducted. Mean direct medical, direct non medical, indirect and total costs were 1,876, 794, 2,904 and 5,574 euros/patient/year, respectively. Total costs were in significant linear relationship with health assessment questionnaire score and psoriatic area severity index. Costs of RA were higher in all domains than of PsA. Our study was the first from the Eastern European region that provides cost-of-illness data on PsA. Our study revealed that functional status and severity of skin symptoms were the key cost drivers. The costs of PsA in Hungary were lower than in the high-income European countries.
Indexed as
Identifiers
19381635What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.